Cargando...

Effects of the NK(1) Antagonist, Aprepitant, on Response to Oral and Intranasal Oxycodone in Prescription Opioid Abusers

Preclinical studies suggest that the NK(1) receptor may modulate the response to opioids, with NK(1) inactivation leading to decreased opioid reinforcement, tolerance and withdrawal. Aprepitant is a selective NK(1) antagonist currently marketed for clinical use as an anti-emetic. This 6-week inpatie...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Addict Biol
Main Authors: Walsh, Sharon L., Heilig, Markus, Nuzzo, Paul A., Henderson, Pam, Lofwall, Michelle R.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4354863/
https://ncbi.nlm.nih.gov/pubmed/22260216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1369-1600.2011.00419.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!